InVision Precision Cardiac Amyloid vs Irregular Rhythm Notification Feature (IRNF)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

InVision Precision Cardiac Amyloid

by InVision Medical Technology

Irregular Rhythm Notification Feature (IRNF)

by Apple

AI Verdict

Tool A is a specialized clinical diagnostic aid for cardiac amyloidosis, designed for integration into echocardiography lab workflows to assist clinicians. Tool B is a consumer-facing wearable feature that screens for irregular heart rhythms suggestive of AFib, empowering users to proactively engage with their physicians. While both leverage AI for cardiovascular health and are FDA-cleared, their distinct target users, deployment models, and specific disease focuses make them suitable for different points in the healthcare journey.

Choose InVision Precision Cardiac Amyloid if…

Choose InVision Precision Cardiac Amyloid if your cardiology practice or echocardiography lab requires an AI-powered, FDA-cleared solution for the precise and early detection of cardiac amyloidosis. This tool is ideal for clinicians aiming to enhance diagnostic accuracy and improve patient outcomes for this life-threatening and often underdiagnosed disease, integrating seamlessly into existing echocardiography workflows.

View InVision Precision Cardiac Amyloid →

Choose Irregular Rhythm Notification Feature (IRNF) if…

Choose the Irregular Rhythm Notification Feature if you are a healthcare provider encouraging proactive patient engagement in screening for potential AFib, or if you are an individual seeking an accessible, over-the-counter tool for continuous background monitoring of irregular heart rhythms. This feature empowers users with notifications to facilitate timely discussions with their physicians, leveraging a widely adopted wearable device for early awareness.

View Irregular Rhythm Notification Feature (IRNF) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	InVision Precision Cardiac Amyloid	Irregular Rhythm Notification Feature (IRNF)
Pricing	Unknown	Included with apple watch purchase
Deployment	Cloud or on-premise	Device-based (Apple Watch), integrated with the iPhone Health app.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Irregular Rhythm Notification Feature (IRNF)

Tool B (IRNF) is designed for over-the-counter use and is integrated into the widely adopted Apple Watch and iPhone Health app, making it highly accessible and easy for general consumers to use. Tool A (InVision) is integrated into specialized clinical workflows for echocardiography labs, indicating a more professional and less broadly accessible user experience.

Clinical Value

InVision Precision Cardiac Amyloid

Tool A (InVision) aims for earlier detection and reduction of misdiagnosis for cardiac amyloidosis, a life-threatening disease, with its AI algorithm peer-reviewed and published in JAMA Cardiology. Tool B (IRNF) is a screening tool for irregular heart rhythms suggestive of AFib, empowering users to facilitate discussions with physicians, but it does not provide a diagnosis itself.

Pricing & Value

Irregular Rhythm Notification Feature (IRNF)

Tool B (IRNF) is included with the purchase of an Apple Watch, meaning there is no additional recurring cost for the feature itself. Tool A (InVision) requires a separate subscription, starting at $49/month, representing a direct and ongoing cost for its specialized clinical application.

Enterprise Readiness

InVision Precision Cardiac Amyloid

Tool A (InVision) is explicitly designed as a Software as a Medical Device (SaMD) for integration into clinical workflows, is HIPAA compliant, and offers enterprise pricing and volume discounts. Tool B (IRNF), while FDA-cleared, is a consumer feature and Apple does not offer a Business Associate Agreement (BAA), placing the burden of HIPAA compliance on the covered entity for data shared from the device.

Innovation

InVision Precision Cardiac Amyloid

Tool A (InVision) applies advanced AI to a complex diagnostic challenge in echocardiography for a rare and difficult-to-diagnose condition (cardiac amyloidosis), backed by peer-reviewed research in JAMA Cardiology. Tool B's (IRNF) innovation lies more in democratizing heart rhythm screening through a widely accessible consumer device, rather than a breakthrough in diagnostic methodology itself.

Support & Docs

Irregular Rhythm Notification Feature (IRNF)

Tool B (IRNF) benefits from Apple's extensive consumer support ecosystem, offering readily available and detailed 'Instructions for Use' and an 'onboarding process with educational materials' for its users. While Tool A (InVision) as a professional SaMD would require robust support, specific public-facing documentation and support channels are less explicitly detailed in the available information compared to Apple's comprehensive resources.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	InVision Precision Cardiac Amyloid	Irregular Rhythm Notification Feature (IRNF)
Name	InVision Precision Cardiac Amyloid	Irregular Rhythm Notification Feature (IRNF)
Company	InVision Medical Technology Corporation	Apple
Primary Detection Target	Cardiac amyloidosis	Irregular heart rhythms suggestive of AFib
Key Feature: AI/ML Aspect	AI-powered detection of cardiac amyloidosis; Evidence-based AI algorithm, peer-reviewed and published.	Machine learning-based algorithm for improved AFib differentiation (IRNF 2.0).
Key Feature: User/Clinician Interaction	Aids clinicians in diagnosing and assessing patients with heart failure symptoms.	Empowers users with notifications to facilitate discussions with their physicians; Ability for users to export and share health data with physicians.
Specialties	Cardiology, Radiology	Cardiology, Family Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring InVision Precision Cardiac Amyloid and Irregular Rhythm Notification Feature (IRNF).

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's existing clinical workflow, and what specific actions are physicians expected to take based on their outputs?

InVision Precision Cardiac Amyloid integrates into echocardiography lab workflows, providing AI-powered analysis of echo studies to aid in the diagnosis of cardiac amyloidosis, prompting physicians to consider specific diagnostic pathways. The Irregular Rhythm Notification Feature (IRNF) operates on a patient's Apple Watch, notifying them of irregular rhythms suggestive of AFib, which they can then share with their physician to initiate further clinical evaluation.

What is the clinical accuracy and specificity of each tool for its intended purpose, and how does this impact a physician's diagnostic confidence or need for confirmatory testing?

InVision Precision Cardiac Amyloid offers AI-powered detection of cardiac amyloidosis from echocardiograms, with its evidence-based algorithm peer-reviewed and published in JAMA Cardiology, aiming for earlier and more precise diagnosis to enhance diagnostic confidence. The IRNF screens for irregular rhythms suggestive of AFib, with studies showing varying positive predictive values (e.g., 84% in the Apple Heart Study), but it requires further clinical evaluation and diagnostic testing by a physician for a definitive diagnosis.

Which medical specialties are best suited to leverage each tool, and for what specific patient populations or clinical scenarios?

InVision Precision Cardiac Amyloid is primarily suited for Cardiology and Radiology, focusing on patients with heart failure symptoms who require echocardiogram evaluation for potential cardiac amyloidosis, a life-threatening and often underdiagnosed disease. The IRNF is broadly applicable across Cardiology, Family Medicine, and Internal Medicine, serving a general population of Apple Watch users aged 22 and over for proactive screening of irregular heart rhythms suggestive of AFib.

What is the expected learning curve for clinical staff to effectively utilize each tool, and what kind of ongoing support or training is provided?

For InVision Precision Cardiac Amyloid, the learning curve involves integrating the software into existing echocardiography workflows and training staff on interpreting its AI-powered analysis, with support likely provided by InVision Medical Technology. For the IRNF, the primary interaction is patient-driven, with physicians primarily receiving and interpreting patient-shared data, thus minimizing a direct clinical staff learning curve, though physicians may need to understand how to interpret the notifications.

Beyond standard compliance, what specific security measures protect patient data, and do these tools offer audit-trail features relevant for clinical practice?

The Irregular Rhythm Notification Feature leverages Apple HealthKit's encryption for data at rest on the device and during iCloud sync, providing a secure framework for patient-controlled data sharing, with data being end-to-end encrypted with two-factor authentication. While specific audit-trail features for InVision Precision Cardiac Amyloid are not detailed, as an enterprise-level medical device software integrated into clinical workflows, it would typically include robust security protocols and likely offer audit-trail capabilities for clinical use.

How quickly can a practice expect to realize clinical value from each tool, and what are the key considerations for implementing them across multiple clinical sites?

InVision Precision Cardiac Amyloid, by integrating into existing echo labs, can provide immediate AI-powered analysis on current studies, offering rapid time-to-value for cardiac amyloidosis detection and requiring coordinated enterprise rollout for multi-site implementation. The IRNF's value is realized as individual patients use their Apple Watches for AFib screening, with physicians receiving data as patients choose to share it, making multi-site 'implementation' a matter of patient adoption rather than system deployment.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring InVision Precision Cardiac Amyloid or Irregular Rhythm Notification Feature (IRNF)

Backers

Who funded each tool's parent company.

Irregular Rhythm Notification Feature (IRNF)

Transformer VC